Refine
Year of publication
- 2018 (88) (remove)
Language
- English (88)
Has Fulltext
- yes (88)
Is part of the Bibliography
- no (88)
Keywords
- Heavy Ion Experiments (5)
- glioblastoma (2)
- 2-deoxyglucose (2-DG) (1)
- ALK-rearranged NSCLC (1)
- Biomarker (1)
- Cementation (1)
- Ceramic (1)
- Comparative genomics (1)
- Evolution (1)
- Fungi (1)
- Gene expression profiling (1)
- Heavy-ion collision (1)
- High-throughput screening (1)
- Hyperons (1)
- Immunology (1)
- Minimal invasive (1)
- Molecular medicine (1)
- Molecular modelling (1)
- Monolithic crown (1)
- Non-small cell lung cancer (1)
- Nucleus (1)
- Osimertinib (1)
- Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (1)
- Plant symbiosis (1)
- Proteins (1)
- Proton (1)
- RNASolution-state NMR (1)
- Strangeness (1)
- TP53 mutation status (1)
- Target validation (1)
- Tet-inducible system (1)
- Warburg effect (1)
- Zirconia (1)
- aegean (1)
- coastal geomorphology (1)
- doxycycline (1)
- ectosomes (1)
- electrical resistivity tomography (1)
- exosomes (1)
- extracellular vesicles (1)
- foraminifera (1)
- geophysical prospections (1)
- glycolysis (1)
- guidelines (1)
- head-and-neck cancer (1)
- heavy ion experiments (1)
- hypoxia-induced cell death (1)
- immunotherapy (1)
- inducible gene expression (1)
- interferon gamma (1)
- isocaloric ketogenic diet (1)
- lung cancer (1)
- magnetic gradiometry (1)
- metabolic cancer therapy (1)
- metastasis (1)
- micropalaeontology (1)
- microparticles (1)
- microvesicles (1)
- minimal information requirements (1)
- mitochondria (1)
- neoepitopes (1)
- proteomics (1)
- quark gluon plasma (1)
- reproducibility (1)
- rigor (1)
- sequential ALK-inhibitor therapy (1)
- standardization (1)
- tetracycline (1)
- tumor metabolism (1)
- tumor-infiltrating lymphocytes (1)
Institute
Modification of SMN2 exon 7 (E7) splicing is a validated therapeutic strategy against spinal muscular atrophy (SMA). However, a target-based approach to identify small-molecule E7 splicing modifiers has not been attempted, which could reveal novel therapies with improved mechanistic insight. Here, we chose as a target the stem-loop RNA structure TSL2, which overlaps with the 5′ splicing site of E7. A small-molecule TSL2-binding compound, homocarbonyltopsentin (PK4C9), was identified that increases E7 splicing to therapeutic levels and rescues downstream molecular alterations in SMA cells. High-resolution NMR combined with molecular modelling revealed that PK4C9 binds to pentaloop conformations of TSL2 and promotes a shift to triloop conformations that display enhanced E7 splicing. Collectively, our study validates TSL2 as a target for small-molecule drug discovery in SMA, identifies a novel mechanism of action for an E7 splicing modifier, and sets a precedent for other splicing-mediated diseases where RNA structure could be similarly targeted.
Throughout mankind’s history, the need to secure and protect the home settlement was an essential one. This holds especially true for the city of Ainos (modern Enez) in Turkish Thrace. Due to its continuous settlement history since the 7th/6th century BC, several different types of city walls were built—sometimes even on top of each other—several of which have been preserved over time. To decipher the construction style, the course and the age of a buried city wall segment in the southern part of the former city, a geoscientific multi-proxy approach including magnetic gradiometer (MG) and electrical resistivity tomography (ERT) measurements in combination with granulometrical, sedimentological and microfaunistical investigations on sediment cores was applied. We were able to (1) present reasonable arguments for its Hellenistic age; (2) reveal the course of this wall segment and extrapolate it further north into a less studied area; and (3) demonstrate that in this near-coastal area, the former swampy terrain had been consolidated for constructing the wall. Our multi-proxy approach serves as a valuable example for investigating buried structures in archaeological contexts, avoiding a less-economical, time-consuming, or even forbidden excavation.
Purpose: All-ceramic restorations required extensive tooth preparation. The purpose of this in vitro study was to investigate a minimally invasive preparation and thickness of monolithic zirconia crowns, which would provide sufficient mechanical endurance and strength.
Materials and methods: Crowns with thickness of 0.2 mm (group 0.2, n=32) or of 0.5 mm (group 0.5, n=32) were milled from zirconia and fixed with resin-based adhesives (groups 0.2A, 0.5A) or zinc phosphate cements (groups 0.2C, 0.5C). Half of the samples in each subgroup (n=8) underwent thermal cycling and mechanical loading (TCML)(TC: 5℃ and 55℃, 2×3,000 cycles, 2 min/cycle; ML: 50 N, 1.2×106 cycles), while the other samples were stored in water (37℃/24 h). Survival rates were compared (Kaplan-Maier). The specimens surviving TCML were loaded to fracture and the maximal fracture force was determined (ANOVA; Bonferroni; α=.05). The fracture mode was analyzed.
Results: In both 0.5 groups, all crowns survived TCML, and the comparison of fracture strength among crowns with and without TCML showed no significant difference (P=.628). Four crowns in group 0.2A and all of the crowns in group 0.2C failed during TCML. The fracture strength after 24 hours of the cemented 0.2 mm-thick crowns was significantly lower than that of adhesive bonded crowns. All cemented crowns provided fracture in the crown, while about 80% of the adhesively bonded crowns fractured through crown and die.
Conclusion: 0.5 mm thick monolithic crowns possessed sufficient strength to endure physiologic performance, regardless of the type of cementation. Fracture strength of the 0.2 mm cemented crowns was too low for clinical application.
Tuberaceae is one of the most diverse lineages of symbiotic truffle-forming fungi. To understand the molecular underpinning of the ectomycorrhizal truffle lifestyle, we compared the genomes of Piedmont white truffle (Tuber magnatum), Périgord black truffle (Tuber melanosporum), Burgundy truffle (Tuber aestivum), pig truffle (Choiromyces venosus) and desert truffle (Terfezia boudieri) to saprotrophic Pezizomycetes. Reconstructed gene duplication/loss histories along a time-calibrated phylogeny of Ascomycetes revealed that Tuberaceae-specific traits may be related to a higher gene diversification rate. Genomic features in Tuber species appear to be very similar, with high transposon content, few genes coding lignocellulose-degrading enzymes, a substantial set of lineage-specific fruiting-body-upregulated genes and high expression of genes involved in volatile organic compound metabolism. Developmental and metabolic pathways expressed in ectomycorrhizae and fruiting bodies of T. magnatum and T. melanosporum are unexpectedly very similar, owing to the fact that they diverged ~100 Ma. Volatile organic compounds from pungent truffle odours are not the products of Tuber-specific gene innovations, but rely on the differential expression of an existing gene repertoire. These genomic resources will help to address fundamental questions in the evolution of the truffle lifestyle and the ecology of fungi that have been praised as food delicacies for centuries.
The first measurement of e+e− pair production at mid-rapidity (|ηe| < 0.8) in pp collisions at s√=7 TeV with ALICE at the LHC is presented. The dielectron production is studied as a function of the invariant mass (mee < 3.3 GeV/c2), the pair transverse momentum (pT,ee < 8 GeV/c), and the pair transverse impact parameter (DCAee), i.e., the average distance of closest approach of the reconstructed electron and positron tracks to the collision vertex, normalised to its resolution. The results are compared with the expectations from a cocktail of known hadronic sources and are well described when PYTHIA is used to generate the heavy-flavour contributions. In the low-mass region (0.14 < mee < 1.1 GeV/c2), prompt and non-prompt e+e− sources can be separated via the DCAee. In the intermediate-mass region (1.1 < mee < 2.7 GeV/c2), a double-differential fit to the data in mee and pT,ee and a fit of the DCAee distribution allow the total cc¯¯ and bb¯¯¯ cross sections to be extracted. Two different event generators, PYTHIA and POWHEG, can reproduce the shape of the two-dimensional mee and pT,ee spectra, as well as the shape of the DCAee distribution, reasonably well. However, differences in the cc¯¯ and bb¯¯¯ cross sections are observed when using the generators to extrapolate to full phase space. Finally, the ratio of inclusive to decay photons is studied via the measurement of virtual direct photons in the transverse-momentum range 1 < pT < 8 GeV/c. This is found to be unity within the statistical and systematic uncertainties and consistent with expectations from next-to-leading order perturbative quantum chromodynamic calculations.
Medium modification of the shape of small-radius jets in central Pb-Pb collisions at √sNN = 2.76 TeV
(2018)
We present the measurement of a new set of jet shape observables for track-based jets in central Pb-Pb collisions at sNN−−−√=2.76 TeV. The set of jet shapes includes the first radial moment or angularity, g; the momentum dispersion, pTD; and the difference between the leading and sub-leading constituent track transverse momentum, LeSub. These observables provide complementary information on the jet fragmentation and can constrain different aspects of the theoretical description of jet-medium interactions. The jet shapes were measured for a small resolution parameter R = 0.2 and were fully corrected to particle level. The observed jet shape modifications indicate that in-medium fragmentation is harder and more collimated than vacuum fragmentation as obtained by PYTHIA calculations, which were validated with the measurements of the jet shapes in proton-proton collisions at s√=7 TeV. The comparison of the measured distributions to templates for quark and gluon-initiated jets indicates that in-medium fragmentation resembles that of quark jets in vacuum. We further argue that the observed modifications are not consistent with a totally coherent energy loss picture where the jet loses energy as a single colour charge, suggesting that the medium resolves the jet structure at the angular scales probed by our measurements (R = 0.2). Furthermore, we observe that small-R jets can help to isolate purely energy loss effects from other effects that contribute to the modifications of the jet shower in medium such as the correlated background or medium response.
Neutral pion and η meson invariant differential yields were measured in non-single diffractive p–Pb collisions at sNN−−−√ = 5.02 TeV with the ALICE experiment at the CERN LHC. The analysis combines results from three complementary photon measurements, utilizing the PHOS and EMCal calorimeters and the Photon Conversion Method. The invariant differential yields of π0 and η meson inclusive production are measured near mid-rapidity in a broad transverse momentum range of 0.3<pT<20 GeV/c and 0.7<pT<20 GeV/c, respectively. The measured η/π0 ratio increases with pT and saturates for pT > 4 GeV/c at 0.483±0.015stat±0.015sys. A deviation from mT scaling is observed for pT< 2 GeV/c. The measured η/π0 ratio is consistent with previous measurements from proton-nucleus and pp collisions over the full pT range. The measured η/π0 ratio at high pT also agrees within uncertainties with measurements from nucleus–nucleus collisions. The π0 and η yields in p–Pb relative to the scaled pp interpolated reference, RpPb, are presented for 0.3<pT< 20 GeV/c and 0.7<pT< 20 GeV/c, respectively. The results are compared with theoretical model calculations. The values of RpPb are consistent with unity for transverse momenta above 2 GeV/c. These results support the interpretation that the suppressed yield of neutral mesons measured in Pb–Pb collisions at LHC energies is due to parton energy loss in the hot QCD medium.
Objectives: In the AURA3 trial, individuals received osimertinib 80 mg once daily or chemotherapy for advanced non-small cell lung cancer. Here, we explore patient-reported symptoms possibly related to treatment.
Materials and methods: AURA3 was an open-label, randomized phase III trial involving 419 patients. As part of the trial’s exploratory objectives, individuals were asked to complete the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) electronically, first weekly for 18 weeks and then every 3 weeks for up to 57 weeks, subject to the availability of validated local-language versions (English, German, Japanese and Spanish versions were available).
Results: In total, 161 patients (38%; 102 receiving osimertinib, 59 receiving chemotherapy) provided data for PRO-CTCAE analyses (mean age: 64 years; 63% women). Diarrhea was reported more commonly with osimertinib than with chemotherapy, and was mostly graded as occurring rarely or occasionally. Decreased appetite was reported less commonly with osimertinib than with chemotherapy. The proportion of patients reporting nausea changed little from baseline with osimertinib and increased with chemotherapy. Few patients reported vomiting. Both nausea and vomiting were generally graded as mild in severity. Fatigue was reported less commonly with osimertinib than with chemotherapy, and was mostly graded as mild or moderate. Of patients reporting fatigue, the proportion grading it as interfering at least ‘somewhat’ with their usual or daily activities was lower with osimertinib than with chemotherapy.
Conclusion: Symptoms were generally mild and not frequent, with some differences in symptom patterns between the two treatment groups. The results support and complement the AURA3 trial data and give insight into patients’ experience with treatment.
Cancer metabolism is characterized by extensive glucose consumption through aerobic glycolysis. No effective therapy exploiting this cancer trait has emerged so far, in part, due to the substantial side effects of the investigated drugs. In this study, we examined the side effects of a combination of isocaloric ketogenic diet (KD) with the glycolysis inhibitor 2-deoxyglucose (2-DG). Two groups of eight athymic nude mice were either fed a standard diet (SD) or a caloric unrestricted KD with a ratio of 4 g fat to 1 g protein/carbohydrate. 2-DG was investigated in commonly employed doses of 0.5 to 4 g/kg and up to 8 g/kg. Ketosis was achieved under KD (ketone bodies: SD 0.5 ± 0.14 mmol/L, KD 1.38 ± 0.28 mmol/L, p < 0.01). The intraperitoneal application of 4 g/kg of 2-DG caused a significant increase in blood glucose, which was not prevented by KD. Sedation after the 2-DG treatment was observed and a behavioral test of spontaneous motion showed that KD reduced the sedation by 2-DG (p < 0.001). A 2-DG dose escalation to 8 g/kg was lethal for 50% of the mice in the SD and for 0% of the mice in the KD group (p < 0.01). A long-term combination of KD and an oral 1 or 2 g 2-DG/kg was well-tolerated. In conclusion, KD reduces the sedative effects of 2-DG and dramatically increases the maximum tolerated dose of 2-DG. A continued combination of KD and anti-glycolytic therapy is feasible. This is, to our knowledge, the first demonstration of increased tolerance to glycolysis inhibition by KD.
Inducible gene expression is an important tool in molecular biology research to study protein function. Most frequently, the antibiotic doxycycline is used for regulation of so-called tetracycline (Tet)-inducible systems. In contrast to stable gene overexpression, these systems allow investigation of acute and reversible effects of cellular protein induction. Recent reports have already called for caution when using Tet-inducible systems as the employed antibiotics can disturb mitochondrial function and alter cellular metabolism by interfering with mitochondrial translation. Reprogramming of energy metabolism has lately been recognized as an important emerging hallmark of cancer and is a central focus of cancer research. Therefore, the scope of this study was to systematically analyze dose-dependent metabolic effects of doxycycline on a panel of glioma cell lines with concomitant monitoring of gene expression from Tet-inducible systems. We report that doxycycline doses commonly used with inducible expression systems (0.01–1 µg/mL) substantially alter cellular metabolism: Mitochondrial protein synthesis was inhibited accompanied by reduced oxygen and increased glucose consumption. Furthermore, doxycycline protected human glioma cells from hypoxia-induced cell death. An impairment of cell growth was only detectable with higher doxycycline doses (10 µg/mL). Our findings describe settings where doxycycline exerts effects on eukaryotic cellular metabolism, limiting the employment of Tet-inducible systems.